Cerebrovascular Profile Assessment in Parkinson’s Disease Patients

E-ISSN： 1996-3181|13|4|712-717

ISSN： 1871-5273

Source： CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol.13, Iss.4, 2014-06, pp. : 712-717

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hepatotoxic profile of catecholOmethyltranferase inhibitors in Parkinson’s disease

By Benabou Reina Waters Cheryl

Expert Opinion on Drug Safety, Vol. 2, Iss. 3, 2003-05 ,pp. : 263-267

Informa Healthcare

Access to resources Recommend Favorite

Levodopa-Induced Response Fluctuations in Patients with Parkinsons Disease: Strategies for Management

By van Laar T.

CNS Drugs, Vol. 17, Iss. 7, 2003-01 ,pp. : 475-489

Adis International

Access to resources Recommend Favorite

Combating psychosis in Parkinson’s disease patients: the use of antipsychotic drugs

By Chou Kelvin L Fernandez Hubert H

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 4, 2006-04 ,pp. : 339-349

Informa Healthcare

Access to resources Recommend Favorite

Entacapone in the management of Parkinson’s disease

By Waters Cheryl Henchcliffe Claire

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. : 957-963

Informa Healthcare

Access to resources Recommend Favorite

Dopaminergic substitution in Parkinson’s disease

By Müller Thomas

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 10, 2002-10 ,pp. : 1393-1403

Informa Healthcare

Access to resources Recommend Favorite